Indications for use:
Malignant melanoma (cancer that develops from pigment-forming cells), Hodgkin’s disease (malignant disease of lymphoid tissue) and leukosarcoma (malignant tumor arising from immature lymphoid cells) – as part of combination therapy.
Antitumor cytostatic (an agent that suppresses cell division), which has a dual mechanism of action. The drug inhibits the synthesis of DNA (deoxyribonucleic acid, which is contained mainly in the cell nucleus and is the carrier of gene information) and has alkylating properties (causes chemical processes in the cell, leading to a violation of DNA stability).
Dacarbazine (Dacarbazine) method of administration and doses:
Dacarbazine is administered intravenously, and in some localizations of the tumor process intraarterially.
Monotherapy (treatment with one product -) is carried out in cycles of 5-6 days at a dose of 150 to 250 mg / m2 every day. The interval between cycles is 21 days.
As part of combination therapy, cycles of 4-5 days are most often carried out. The dose of dacarbazine is 100 mg/m2 every day. The interval between cycles is 21 days.
In combination therapy, the product is used primarily in combination with bleomyin, cisplatin, fluorouracil, vincristine, prednisolone.
During the period of treatment and afterwards, it is necessary to carry out all laboratory studies, and special attention should be paid to the hematopoietic system to prevent manifestations of a hematotoxic effect (damaging effects on the hematopoietic organs).
The frequency and intensity of local reactions decrease with the introduction of dacarbazine with a perfusion solution.
With simultaneous use with phenobarbital, azathioprim, mercaptopurine, it is possible to increase the toxic effect of dacarbazine.
Dacarbazine (Dacarbazine) side effects:
Anorexia (loss of appetite), nausea, vomiting, constipation; thrombosis (formation of a blood clot in a vessel) of the hepatic veins and necrosis of hepatocytes (necrosis of liver cells) are extremely rare; granulocytopenia (decrease in the content of granuloiites in the blood) and thrombocytopenia (decrease in the number of platelets in the blood) – the intensity of these manifestations depends on the dose of the administered product; pain at the injection site; general disorders such as pseudoinfluenza syndrome, accompanied by asthenia (weakness), headaches and muscle pain, increased body temperature; amenorrhea (absence of menstruation), azoospermia (absence of spermatozoa in semen).